Pacific Biosciences Of California, Inc. (PACB)

$1.72

+0.09

(+5.52%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $1.67
    $1.75
    $1.72
    downward going graph

    3.2%

    Downside

    Day's Volatility :4.86%

    Upside

    1.71%

    downward going graph
  • $1.16
    $10.65
    $1.72
    downward going graph

    32.56%

    Downside

    52 Weeks Volatility :89.11%

    Upside

    83.85%

    downward going graph

Returns

PeriodPacific Biosciences Of California, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
24.43%
4.9%
0.0%
6 Months
-51.34%
5.8%
0.0%
1 Year
-80.17%
17.8%
0.0%
3 Years
-93.51%
20.1%
-20.6%

Highlights

Market Capitalization
444.2M
Book Value
$1.81
Earnings Per Share (EPS)
-1.5
PEG Ratio
-0.17
Wall Street Target Price
2.83
Profit Margin
-211.99%
Operating Margin TTM
-176.74%
Return On Assets TTM
-11.24%
Return On Equity TTM
-70.57%
Revenue TTM
188.9M
Revenue Per Share TTM
0.71
Quarterly Revenue Growth YOY
-24.3%
Gross Profit TTM
53.5M
EBITDA
-267.7M
Diluted Eps TTM
-1.5
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.37
EPS Estimate Next Year
-0.69
EPS Estimate Current Quarter
-0.23
EPS Estimate Next Quarter
-0.21

Analyst Recommendation

Buy
    55%Buy
    45%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Pacific Biosciences Of California, Inc.(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
14
15
Hold
9
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 64.53%

Current $1.72
Target $2.83

Company Financials

FY18Y/Y Change
Revenue
78.6M
↓ 15.88%
Net Income
-102.6M
↑ 11.25%
Net Profit Margin
-130.44%
↓ 31.81%
FY19Y/Y Change
Revenue
90.9M
↑ 15.6%
Net Income
-77.8M
↓ 24.12%
Net Profit Margin
-85.62%
↑ 44.82%
FY20Y/Y Change
Revenue
78.9M
↓ 13.2%
Net Income
29.4M
↓ 137.78%
Net Profit Margin
37.27%
↑ 122.89%
FY21Y/Y Change
Revenue
130.5M
↑ 65.43%
Net Income
-181.2M
↓ 716.34%
Net Profit Margin
-138.85%
↓ 176.12%
FY22Y/Y Change
Revenue
128.3M
↓ 1.69%
Net Income
-296.9M
↑ 63.85%
Net Profit Margin
-231.43%
↓ 92.58%
FY23Y/Y Change
Revenue
200.5M
↑ 56.29%
Net Income
-306.7M
↑ 3.3%
Net Profit Margin
-152.97%
↑ 78.46%
Q1 FY23Q/Q Change
Revenue
38.9M
↑ 42.21%
Net Income
-81.1M
↑ 1.64%
Net Profit Margin
-208.61%
↑ 83.28%
Q2 FY23Q/Q Change
Revenue
47.6M
↑ 22.3%
Net Income
-69.8M
↓ 13.94%
Net Profit Margin
-146.79%
↑ 61.82%
Q3 FY23Q/Q Change
Revenue
55.7M
↑ 17.06%
Net Income
-66.9M
↓ 4.24%
Net Profit Margin
-120.07%
↑ 26.72%
Q4 FY23Q/Q Change
Revenue
58.4M
↑ 4.79%
Net Income
-82.0M
↑ 22.65%
Net Profit Margin
-140.55%
↓ 20.48%
Q1 FY24Q/Q Change
Revenue
38.8M
↓ 33.5%
Net Income
-78.2M
↓ 4.68%
Net Profit Margin
-201.44%
↓ 60.89%
Q2 FY24Q/Q Change
Revenue
36.0M
↓ 7.21%
Net Income
-173.3M
↑ 121.7%
Net Profit Margin
-481.27%
↓ 279.83%
FY18Y/Y Change
Total Assets
170.3M
↑ 18.18%
Total Liabilities
56.2M
↓ 3.05%
FY19Y/Y Change
Total Assets
148.0M
↓ 13.09%
Total Liabilities
93.1M
↑ 65.56%
FY20Y/Y Change
Total Assets
414.0M
↑ 179.74%
Total Liabilities
78.5M
↓ 15.66%
FY21Y/Y Change
Total Assets
2.0B
↑ 384.8%
Total Liabilities
1.2B
↑ 1449.24%
FY22Y/Y Change
Total Assets
1.8B
↓ 11.95%
Total Liabilities
1.2B
↓ 0.97%
FY23Y/Y Change
Total Assets
1.7B
↓ 1.19%
Total Liabilities
1.0B
↓ 13.24%
Q1 FY23Q/Q Change
Total Assets
1.9B
↑ 7.32%
Total Liabilities
1.2B
↑ 0.01%
Q2 FY23Q/Q Change
Total Assets
1.8B
↓ 2.57%
Total Liabilities
1.2B
↑ 0.11%
Q3 FY23Q/Q Change
Total Assets
1.9B
↑ 2.75%
Total Liabilities
1.1B
↓ 5.89%
Q4 FY23Q/Q Change
Total Assets
1.7B
↓ 8.02%
Total Liabilities
1.0B
↓ 7.92%
Q1 FY24Q/Q Change
Total Assets
1.7B
↓ 4.36%
Total Liabilities
1.0B
↓ 2.28%
Q2 FY24Q/Q Change
Total Assets
1.5B
↓ 9.61%
Total Liabilities
1.0B
↓ 0.4%
FY18Y/Y Change
Operating Cash Flow
-66.4M
↓ 1.61%
Investing Cash Flow
-38.4M
↑ 2379.99%
Financing Cash Flow
107.2M
↑ 55.77%
FY19Y/Y Change
Operating Cash Flow
-78.3M
↑ 17.89%
Investing Cash Flow
62.0M
↓ 261.52%
Financing Cash Flow
26.5M
↓ 75.23%
FY20Y/Y Change
Operating Cash Flow
19.5M
↓ 124.9%
Investing Cash Flow
-219.3M
↓ 453.48%
Financing Cash Flow
251.8M
↑ 848.62%
FY21Y/Y Change
Operating Cash Flow
-111.2M
↓ 670.07%
Investing Cash Flow
-678.5M
↑ 209.38%
Financing Cash Flow
1.2B
↑ 364.42%
FY22Y/Y Change
Operating Cash Flow
-263.2M
↑ 136.74%
Investing Cash Flow
116.1M
↓ 117.11%
Financing Cash Flow
9.6M
↓ 99.18%
Q1 FY23Q/Q Change
Operating Cash Flow
-94.7M
↑ 56.34%
Investing Cash Flow
-72.6M
↓ 190.24%
Financing Cash Flow
196.0M
↑ 23830.28%
Q2 FY23Q/Q Change
Operating Cash Flow
-41.7M
↓ 55.92%
Investing Cash Flow
-98.6M
↑ 35.89%
Financing Cash Flow
-4.7M
↓ 102.41%

Technicals Summary

Sell

Neutral

Buy

Pacific Biosciences Of California, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pacific Biosciences Of California, Inc.
Pacific Biosciences Of California, Inc.
16.43%
-51.34%
-80.17%
-93.51%
-68.1%
Stryker Corporation
Stryker Corporation
-1.78%
0.17%
32.78%
33.95%
65.12%
Boston Scientific Corp.
Boston Scientific Corp.
3.01%
22.26%
62.19%
97.5%
107.73%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-0.98%
-29.48%
-9.46%
-39.93%
-12.91%
Abbott Laboratories
Abbott Laboratories
-0.77%
0.93%
16.66%
-3.15%
38.49%
Medtronic Plc
Medtronic Plc
-1.81%
3.8%
15.26%
-30.23%
-18.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pacific Biosciences Of California, Inc.
Pacific Biosciences Of California, Inc.
NA
NA
-0.17
-1.37
-0.71
-0.11
NA
1.81
Stryker Corporation
Stryker Corporation
39.2
39.2
2.58
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
68.15
68.15
2.06
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
25.74
25.74
3.44
2.62
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.52
35.52
4.1
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.31
30.31
1.67
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pacific Biosciences Of California, Inc.
Pacific Biosciences Of California, Inc.
Buy
$444.2M
-68.1%
NA
-211.99%
Stryker Corporation
Stryker Corporation
Buy
$135.3B
65.12%
39.2
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$124.4B
107.73%
68.15
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$39.4B
-12.91%
25.74
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$195.3B
38.49%
35.52
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.5B
-18.17%
30.31
12.06%

Insights on Pacific Biosciences Of California, Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 58.35M → 36.01M (in $), with an average decrease of 20.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -78.17M → -173.31M (in $), with an average decrease of 121.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 62.2% return, outperforming this stock by 142.4%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 97.5% return, outperforming this stock by 191.0%

Institutional Holdings

  • ARK Investment Management LLC

    12.19%

  • Vanguard Group Inc

    9.54%

  • BlackRock Inc

    8.66%

  • Madrone Advisors LLC

    8.58%

  • Edmond de Rothschild Holding S.A.

    6.14%

  • Sumitomo Mitsui Trust Holdings Inc

    4.64%

Company Information

pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.

Organization
Pacific Biosciences Of California, Inc.
Employees
796
CEO
Mr. Christian O. Henry M.B.A.
Industry
Health Technology

Discover More

FAQs